High concordance between local and central laboratory testing of biomarkers in the capcetabine (C) plus docetaxel (D) +/-trastuzumab (T) neoadjuvant (XENA) breast cancer (BC) clinical trial Conference

Ross, MS, Slodkowska, E, Sheehan, CE et al. (2008). High concordance between local and central laboratory testing of biomarkers in the capcetabine (C) plus docetaxel (D) +/-trastuzumab (T) neoadjuvant (XENA) breast cancer (BC) clinical trial . MODERN PATHOLOGY, 21 359A-359A.

Industry Collaboration

cited authors

  • Ross, MS; Slodkowska, E; Sheehan, CE; Boguniewicz, AB; Gluck, S; Royce, M; Moisa, C; Ross, JS

authors

date/time interval

  • March 1, 2008 -

publication date

  • January 1, 2008

published in

keywords

  • Life Sciences & Biomedicine
  • Pathology
  • Science & Technology

Location

  • CO, Denver

Conference

  • 97th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology

publisher

  • NATURE PUBLISHING GROUP

start page

  • 359A

end page

  • 359A

volume

  • 21